ANAPTYSBIO, INC. Other Comprehensive Income (Loss), Net of Tax
ANAPTYSBIO, INC. (ANAB) reported Other Comprehensive Income (Loss), Net of Tax of $1.26 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2023-11-02
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was $1.26M.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-06-30 was -$344.00K.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-03-31 was $1.98M.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was -$2.15M.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax for fiscal 2018 was $203.00K.
- ANAPTYSBIO, INC. other comprehensive income (loss), net of tax for fiscal 2017 was -$426.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2023-09-30 | $1.26M 10-Q · filed 2023-11-02 | $917.00K derived: sum of 2 quarters · filed 2023-11-02 | $2.90M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2023-06-30 | -$344.00K 10-Q · filed 2023-11-02 | $1.64M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2023-03-31 | $1.98M 10-Q · filed 2023-11-02 | |||
| 2022-09-30 | -$2.15M 10-Q · filed 2023-11-02 | -$3.57M derived: sum of 2 quarters · filed 2023-11-02 | -$5.58M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | -$1.43M 10-Q · filed 2023-11-02 | -$3.44M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | -$2.01M 10-Q · filed 2023-11-02 | |||
| 2021-09-30 | -$24.00K 10-Q · filed 2022-11-08 | -$89.00K derived: sum of 2 quarters · filed 2022-11-08 | -$196.00K derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | -$65.00K 10-Q · filed 2022-11-08 | -$172.00K derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | -$107.00K 10-Q · filed 2022-11-08 | |||
| 2020-09-30 | -$494.00K 10-Q · filed 2021-11-04 | -$886.00K derived: sum of 2 quarters · filed 2021-11-04 | -$79.00K derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | -$392.00K 10-Q · filed 2021-11-04 | $415.00K derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $807.00K 10-Q · filed 2021-11-04 | |||
| 2019-09-30 | -$94.00K 10-Q · filed 2020-11-04 | $276.00K derived: sum of 2 quarters · filed 2020-11-04 | $703.00K derived: sum of 3 quarters · filed 2020-11-04 | |
| 2019-06-30 | $370.00K 10-Q · filed 2020-11-04 | $797.00K derived: sum of 2 quarters · filed 2020-11-04 | ||
| 2019-03-31 | $427.00K 10-Q · filed 2020-11-04 | |||
| 2018-12-31 | $203.00K 10-K · filed 2019-02-28 | |||
| 2018-09-30 | $136.00K 10-Q · filed 2019-11-08 | $260.00K derived: sum of 2 quarters · filed 2019-11-08 | -$115.00K derived: sum of 3 quarters · filed 2019-11-08 | |
| 2018-06-30 | $124.00K 10-Q · filed 2019-11-08 | -$251.00K derived: sum of 2 quarters · filed 2019-11-08 | ||
| 2018-03-31 | -$375.00K 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | -$426.00K 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |